» Articles » PMID: 24230993

Predictors of Response to Second Generation Antipsychotics in Drug Naïve Patients with Schizophrenia: a 1 Year Follow-up Study in Shanghai

Overview
Journal Psychiatry Res
Specialty Psychiatry
Date 2013 Nov 16
PMID 24230993
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Response and remission are of great importance to patients with first-episode schizophrenia. Although previous researches have revealed characteristics related to medication response, there is rarely data over remission-related factors. We presume that factors correlated to response may also influence remission in 1 year treatment for first-episode schizophrenia. 398 drug-naïve patients met the criteria of schizophrenia using ICD-10 criteria were recruited from Shanghai Mental Health Center and treated with one of three second generation antipsychotics (risperidone, olanzapine or quetiapine). Patients were followed up for 1 year and assessed at 2 weeks, and then 2, 3, 6, 8 and 12 months. Severity of symptom was evaluated using the Chinese version of the Positive and Negative Syndrome Scale (PANSS). Response was defined as a reduction of 50% or more PANSS scores. The 8-item criteria of remission (proposed by the Remission of Schizophrenia Working Group) were used. Logistic regression analysis revealed that shorter duration of untreated psychosis (DUP), longer treatment time, higher baseline PANSS positive score and higher PANSS general pathological scores predicted response, and acute prodromal phase was the independent factor for remission. These results indicate baseline characters that related to response and those related to remission may be different for patients with schizophrenia.

Citing Articles

Symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly.

Correll C, Brieden A, Janetzky W Schizophrenia (Heidelb). 2023; 9(1):80.

PMID: 37935711 PMC: 10630463. DOI: 10.1038/s41537-023-00405-5.


Trajectories of response in schizophrenia-spectrum disorders: A one-year prospective cohort study of antipsychotic effectiveness.

Drosos P, Johnsen E, Bartz-Johannessen C, Larsen T, Reitan S, Rettenbacher M World J Psychiatry. 2022; 12(3):521-532.

PMID: 35433321 PMC: 8968498. DOI: 10.5498/wjp.v12.i3.521.


One-Year Outcome and Adherence to Pharmacological Guidelines in First-Episode Schizophrenia: Results From a Consecutive Cohort Study.

Drosos P, Bronnick K, Joa I, Johannessen J, Johnsen E, Kroken R J Clin Psychopharmacol. 2020; 40(6):534-540.

PMID: 33136922 PMC: 7643791. DOI: 10.1097/JCP.0000000000001303.


Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review.

Bozzatello P, Bellino S, Rocca P Front Psychiatry. 2019; 10:67.

PMID: 30863323 PMC: 6399388. DOI: 10.3389/fpsyt.2019.00067.


Rate of and time to symptomatic remission in first-episode psychosis in Northern Malawi: A STROBE-compliant article.

Kaminga A, Dai W, Liu A, Myaba J, Banda R, Wen S Medicine (Baltimore). 2018; 97(45):e13078.

PMID: 30407306 PMC: 6250544. DOI: 10.1097/MD.0000000000013078.